{
  "ticker": "LLY",
  "target_date": "2025-07-11",
  "actual_date": "2025-07-11",
  "collected_at": "2025-12-08T12:00:16.993848",
  "price": {
    "open": 783.48,
    "high": 792.82,
    "low": 774.36,
    "close": 790.1116943359375,
    "volume": 2852500,
    "change_1d_pct": 0.3,
    "change_7d_pct": 2.21,
    "change_30d_pct": 10.23
  },
  "technicals": {
    "rsi_14": 66.37,
    "sma_20": 783.43,
    "sma_50": 767.99,
    "macd": 3.7,
    "macd_signal": 3.515,
    "macd_histogram": 0.185,
    "bb_upper": 811.93,
    "bb_lower": 754.92,
    "price_vs_sma20_pct": 0.85,
    "price_vs_sma50_pct": 2.88,
    "volume_ratio": 0.95
  },
  "fundamentals": {
    "market_cap": 893615013888,
    "pe_ratio": 48.840275,
    "forward_pe": 43.990734,
    "price_to_book": 37.53125,
    "price_to_sales": 15.039011,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.36,
    "pct_from_52w_low": 59.8
  },
  "macro": {
    "spy": {
      "price": 621.9,
      "change_1d_pct": -0.35,
      "change_7d_pct": 0.51
    },
    "vix": {
      "level": 16.4,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.42
    },
    "dollar_index": {
      "level": 97.85
    },
    "gold": {
      "price": 3356.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "source": "Yahoo",
      "datetime": 1752267366,
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods joi",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    },
    {
      "headline": "Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth",
      "source": "Yahoo",
      "datetime": 1752263576,
      "summary": "Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom",
      "url": "https://finnhub.io/api/news?id=70789419bc3c84dc763db0d47244f564195fdf089100efac92bab14aad4c5362"
    },
    {
      "headline": "Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?",
      "source": "Yahoo",
      "datetime": 1752238440,
      "summary": "LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.",
      "url": "https://finnhub.io/api/news?id=320c0f9f2903b2b864714b44b388f8800802721fef30a616bb68e616eb35ca08"
    },
    {
      "headline": "CGDV: Buy For Value, Stay For Dividend Growth",
      "source": "SeekingAlpha",
      "datetime": 1752235904,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3f2a29284fda1824e0c2b24d458feb13f80c120646789b96b753521e3c2d6cc5"
    },
    {
      "headline": "Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts",
      "source": "SeekingAlpha",
      "datetime": 1752233264,
      "summary": "Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click here to find out why TERN is a Buy.",
      "url": "https://finnhub.io/api/news?id=368947792f663051618f16e0e68054efbc23a017ccbe307868ab1042f9a00f79"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}